Sysmex Corporation (TYO:6869)

Japan flag Japan · Delayed Price · Currency is JPY
1,977.00
-22.50 (-1.13%)
Aug 18, 2025, 3:30 PM JST
-1.13%
Market Cap1.23T
Revenue (ttm)502.43B
Net Income (ttm)47.19B
Shares Out623.61M
EPS (ttm)75.66
PE Ratio26.00
Forward PE20.63
Dividend36.00 (1.80%)
Ex-Dividend DateSep 29, 2025
Volume3,882,400
Average Volume2,554,605
Open2,007.00
Previous Close1,999.50
Day's Range1,965.00 - 2,008.50
52-Week Range1,967.00 - 3,236.00
Beta0.82
RSI21.40
Earnings DateAug 6, 2025

About Sysmex

Sysmex Corporation engages in the development, manufacture, and sale of diagnostic instruments, reagents, and related software. It offers non-clinical blood testing and cell analysis for hematology, such as XN-V series, a software for laboratory animal corresponding to XN series fully automated hematology analyzers; XN-Series, a fully automated flagship hematology analyzers; and Automated hematology analyzer ProCyte Dx for Research applications, a housed in a compact body that simultaneously measures five types of leukocytes and reticulocyte co... [Read more]

Sector Healthcare
Founded 1968
Employees 10,533
Stock Exchange Tokyo Stock Exchange
Ticker Symbol 6869
Full Company Profile

Financial Performance

In 2024, Sysmex's revenue was 508.64 billion, an increase of 10.21% compared to the previous year's 461.51 billion. Earnings were 53.67 billion, an increase of 8.12%.

Financial Statements

News

Sysmex reports FQ1 results

Sysmex (SSMXY) reports FQ1 results: Net sales down 5.6%, operating profit drops 36.5%, and attributable profit declines 58.7%.

12 days ago - Seeking Alpha

Sysmex reports 9M results

6 months ago - Seeking Alpha

Sysmex GAAP EPS of ¥41.70, revenue of ¥242.48B

Sysmex (SSMXY) reports a strong 1H performance with GAAP EPS of ¥41.70 and revenue of ¥242.48B, an impressive 14.0% increase year-over-year.

10 months ago - Seeking Alpha